Test of Cure: Confirming Successful STI Treatment

The basic sequence is:

1. an infection is diagnosed;
2. treatment is given;
3. enough time passes;
4. another test is performed;
5. the result helps show whether the infection is gone.

Not every STI requires a routine test of cure.

The need for one depends on the infection, treatment, symptoms, and individual circumstances.

• test, meaning a medical examination or laboratory analysis;
• cure, meaning successful elimination of an infection.

Examples include:

• The clinician recommended a test of cure after treatment.
• Her test of cure was negative.
• A test of cure may be particularly important when treatment failure is suspected.

Common expressions include:

• perform a test of cure;
• test-of-cure appointment;
• post-treatment testing;
• confirm treatment success;
• negative test of cure.

A test of cure may be considered when:

• treatment failure is possible;
• antibiotic resistance is a concern;
• symptoms continue;
• a nonstandard treatment was used;
• pregnancy changes follow-up recommendations;
• the infection is known to be difficult to eradicate.

It gives clinicians information about whether additional treatment is needed.

Test of Cure

Checks whether the original infection was successfully treated.

Retesting

Usually occurs later to identify reinfection, especially after renewed sexual exposure.

A person may therefore have:

• a successful test of cure;
• another positive test months later because they became infected again.

The later infection does not necessarily mean the first treatment failed.

Some laboratory tests can continue detecting material from microorganisms that are no longer alive.

Testing too early may therefore produce a positive result even though treatment succeeded.

The appropriate interval depends on:

• the STI;
• the test method;
• treatment received;
• current clinical guidance.

Following infection-specific timing recommendations improves interpretation.

However, it may be recommended in particular circumstances, such as:

• pregnancy;
• persistent symptoms;
• concern about medication adherence;
• suspected treatment failure.

Separate retesting later may also be recommended because reinfection with chlamydia is common.

These two follow-up strategies should not be confused.

• the infection site;
• treatment used;
• clinical circumstances.

Some infections, particularly at certain anatomical sites or after alternative treatment regimens, may require follow-up testing.

Antibiotic resistance is especially important with gonorrhea.

A persistent positive result may prompt culture or additional resistance-related evaluation.

Mgen has developed substantial antibiotic resistance, and treatment can sometimes fail.

Follow-up testing may be considered depending on:

• the treatment regimen;
• availability of resistance-guided therapy;
• continuing symptoms;
• current clinical recommendations.

Timing is particularly important because testing too soon after treatment can make results difficult to interpret.

However, a later retest intended to detect reinfection should be distinguished from a test specifically intended to prove immediate microbiological cure.

Partner treatment is important because an untreated partner may transmit the infection back after successful therapy.

Blood-test levels are monitored over time to evaluate whether treatment produced the expected response.

A blood test may remain reactive even after successful treatment.

Therefore, clinicians usually interpret:

• changes in antibody levels;
• treatment history;
• symptoms;
• previous laboratory results

rather than expecting every syphilis blood test to become completely negative.

Instead, HIV treatment is monitored through tests such as:

• viral load;
• CD4 count when appropriate.

An undetectable viral load demonstrates effective viral suppression, not a cure.

This distinction is important when learning sexual-health vocabulary.

Possible explanations include:

• treatment failure;
• reinfection;
• another STI;
• a different medical condition;
• inflammation that persists after the infection has cleared.

A test of cure can sometimes help distinguish these possibilities, but symptoms should not always be interpreted through a single laboratory result.

Possible reasons include:

• antibiotic resistance;
• inadequate drug levels;
• incorrect treatment;
• difficulty completing medication;
• biological factors.

Treatment failure differs from reinfection.

If someone completes treatment successfully and later acquires the infection again from an infected partner, that is reinfection rather than failure of the original treatment.

It can happen when:

• a sexual partner remains untreated;
• treatment is not completed by all relevant partners;
• sexual activity resumes before recommended;
• a new infected partner is encountered.

This is why follow-up STI care may include both partner management and later retesting.

A negative test of cure does not provide immunity against future infection.

Recent partners may need:

• notification;
• testing;
• treatment.

For some infections and jurisdictions, expedited partner therapy may be available.

If an infected partner remains untreated, the original patient may become infected again even after achieving a negative test of cure.

This can help prevent:

• transmission during treatment;
• reinfection;
• exposure of untreated partners.

The recommended interval varies according to the STI and treatment.

Sexual partners may need to complete treatment before sexual contact resumes.

It may represent:

• persistent infection;
• treatment failure;
• reinfection;
• testing performed too early;
• detection of residual genetic material.

Clinicians interpret the result together with:

• treatment history;
• timing;
• symptoms;
• sexual exposure;
• the laboratory test used.

Repeat testing or additional treatment may sometimes be necessary.

However, it does not mean that the person:

• cannot acquire the infection again;
• is protected from other STIs;
• no longer needs appropriate prevention.

Future exposure can lead to another infection.

Condoms, partner treatment, testing, and other preventive strategies may still be relevant.

Resistance can make treatment less reliable for infections such as:

• gonorrhea;
• Mycoplasma genitalium.

If an infection persists despite treatment, laboratory testing may help determine whether resistant organisms are present.

Antibiotics should therefore be used according to current clinical recommendations rather than through repeated self-treatment.

A test of cure and routine retesting are the same thing.
No. A test of cure checks treatment success; later retesting often checks for reinfection.

Testing immediately after treatment gives the most reliable result.
No. Testing too early can sometimes detect residual microbial material.

A positive result always means the medication failed.
No. Reinfection or testing timing may also explain the result.

A negative test of cure means permanent immunity.
No. The infection can be acquired again.

An undetectable HIV viral load is a test of cure.
No. It demonstrates viral suppression, not elimination of HIV.

1. A test of cure can confirm whether an infection remains after treatment.
2. The clinician scheduled follow-up testing after treatment for Mgen.
3. Does every STI require a test of cure?
4. Testing too soon after treatment may complicate interpretation.
5. Reinfection is different from treatment failure.
6. Partner treatment can reduce the chance of becoming infected again.
7. A negative test of cure does not provide immunity from future infection.
8. Understanding test of cure helps readers distinguish treatment success, reinfection, follow-up testing, and STI prevention.

Understanding the difference between treatment failure and reinfection can also prevent unnecessary blame between sexual partners. A later positive result does not automatically prove that the original treatment failed or establish when transmission occurred.

Accurate use of test-of-cure testing supports effective STI treatment, responsible partner care, and informed sexual-health decisions without stigma.